Literature DB >> 8702592

Sphingomyelin inhibits the lecithin-cholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding.

D J Bolin1, A Jonas.   

Abstract

Lecithin-cholesterol acyltransferase (LCAT) catalyzes the formation of cholesterol esters on high density lipoproteins (HDL) and plays a critical role in reverse cholesterol transport. Sphingomyelin, an important constituent of HDL, may regulate the activity of LCAT at any of the key steps of the enzymatic reaction: binding of LCAT to the interface, activation by apo A-I, or inhibition at the catalytic site. In order to clarify the role of sphingomyelin in the regulation of the LCAT reaction and its effects on the structure of apolipoprotein A-I, we prepared reconstituted HDL (rHDL) containing egg phosphatidylcholine, cholesterol, apolipoprotein A-I, and up to 22 mol % sphingomyelin. Because the interfacial properties of substrate particles can dramatically affect LCAT binding and kinetics, we also prepared and analyzed proteoliposome substrates having the same components as the rHDL, except for a 4-fold higher ratio of phospholipid to apolipoprotein A-I. The reaction kinetics of LCAT with the rHDL particles revealed no significant change in the apparent Vmax but showed a concentration-dependent increase in slope of the reciprocal plots and in the apparent Km values with sphingomyelin content. The dissociation constant (Kd) for LCAT with these particles increased linearly with sphingomyelin content up to 22 mol %, changing in parallel with the apparent Km values. No structural changes of apolipoprotein A-I were detected in the particles with increasing content of sphingomyelin, but fluorescence results with lipophilic probes revealed that significant changes in the acyl chain, backbone, and head group regions of the lipid bilayer of the particles are introduced by the addition of sphingomyelin. On the other hand, the proteoliposome substrates also had increased Kdvalues for LCAT at high sphingomyelin contents but compared with the rHDL particles had a 6-10-fold lower affinity for LCAT binding and exhibited kinetics consistent with competitive inhibition by sphingomyelin at the active site. These results show conclusively that the dominant mechanism for the inhibition of LCAT activity with rHDL particles by sphingomyelin is the impaired binding of the enzyme to the interface. The results also underscore the significant differences in the enzyme reaction kinetics with different substrate particles.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702592     DOI: 10.1074/jbc.271.32.19152

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Effects of Replacing Dietary Monounsaturated Fat With Carbohydrate on HDL (High-Density Lipoprotein) Protein Metabolism and Proteome Composition in Humans.

Authors:  Allison B Andraski; Sasha A Singh; Lang Ho Lee; Hideyuki Higashi; Nathaniel Smith; Bo Zhang; Masanori Aikawa; Frank M Sacks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-09-26       Impact factor: 8.311

2.  The interplay between size, morphology, stability, and functionality of high-density lipoprotein subclasses.

Authors:  Giorgio Cavigiolio; Baohai Shao; Ethan G Geier; Gang Ren; Jay W Heinecke; Michael N Oda
Journal:  Biochemistry       Date:  2008-03-27       Impact factor: 3.162

3.  Sequence-specific apolipoprotein A-I effects on lecithin:cholesterol acyltransferase activity.

Authors:  Alexander D Dergunov
Journal:  Mol Cell Biochem       Date:  2013-03-21       Impact factor: 3.396

4.  Regulation of plasma cholesterol esterification by sphingomyelin: effect of physiological variations of plasma sphingomyelin on lecithin-cholesterol acyltransferase activity.

Authors:  Papasani Venkata Subbaiah; Xian-Cheng Jiang; Natalia A Belikova; Buzulagu Aizezi; Zhi Hua Huang; Catherine A Reardon
Journal:  Biochim Biophys Acta       Date:  2012-02-18

5.  Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol.

Authors:  Laxman Yetukuri; Sanni Söderlund; Artturi Koivuniemi; Tuulikki Seppänen-Laakso; Perttu S Niemelä; Marja Hyvönen; Marja-Riitta Taskinen; Ilpo Vattulainen; Matti Jauhiainen; Matej Oresic
Journal:  J Lipid Res       Date:  2010-04-29       Impact factor: 5.922

6.  Phospholipid Component Defines Pharmacokinetic and Pharmacodynamic Properties of Synthetic High-Density Lipoproteins.

Authors:  Maria V Fawaz; Sang Yeop Kim; Dan Li; Ran Ming; Ziyun Xia; Karl Olsen; Irina D Pogozheva; John J G Tesmer; Anna Schwendeman
Journal:  J Pharmacol Exp Ther       Date:  2019-11-27       Impact factor: 4.030

Review 7.  Unraveling the complexities of the HDL lipidome.

Authors:  Anatol Kontush; Marie Lhomme; M John Chapman
Journal:  J Lipid Res       Date:  2013-03-30       Impact factor: 5.922

Review 8.  Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.

Authors:  Robert S Rosenson; H Bryan Brewer; W Sean Davidson; Zahi A Fayad; Valentin Fuster; James Goldstein; Marc Hellerstein; Xian-Cheng Jiang; Michael C Phillips; Daniel J Rader; Alan T Remaley; George H Rothblat; Alan R Tall; Laurent Yvan-Charvet
Journal:  Circulation       Date:  2012-04-17       Impact factor: 29.690

9.  Effect of double bond geometry in sphingosine base on the antioxidant function of sphingomyelin.

Authors:  Papasani V Subbaiah; Debajit Sircar; Ravi S Lankalapalli; Robert Bittman
Journal:  Arch Biochem Biophys       Date:  2008-10-12       Impact factor: 4.013

10.  Cholesterol relieves the inhibitory effect of sphingomyelin on type II secretory phospholipase A2.

Authors:  K S Koumanov; P J Quinn; G Béréziat; C Wolf
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.